We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

82 hedge funds and large institutions have $303M invested in KalVista Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 4

49% more capital invested

Capital invested by funds: $203M → $303M (+$99.6M)

30% more funds holding

Funds holding: 63 → 82 (+19)

0.88% more ownership

Funds ownership: 90.46% → 91.33% (+0.88%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 24

16% less call options, than puts

Call options by funds: $5.6M | Put options by funds: $6.68M

Holders
82
Holders Change
+19
Holders Change %
+30.16%
% of All Funds
1.45%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
22
Reduced
24
Closed
4
Calls
$5.6M
Puts
$6.68M
Net Calls
-$1.08M
Net Calls Change
-$1.08M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.41M
2
LGM
Logos Global Management
California
+$3.26M
3
Franklin Resources
Franklin Resources
California
+$2.84M
4
VC
Vivo Capital
California
+$2.43M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.86M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$2.94M
2
DCM
DAFNA Capital Management
California
-$2.62M
3
GTC
Ghost Tree Capital
New York
-$2.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.74M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$1.44M +$1.3M +75,583 New
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$1.02M +$324K +18,915 +55%
DCM
28
Driehaus Capital Management
Illinois
$950K +$857K +50,000 New
Renaissance Technologies
29
Renaissance Technologies
New York
$939K +$848K +49,428 New
ACM
30
Asymmetry Capital Management
California
$891K +$804K +46,910 New
Bank of New York Mellon
31
Bank of New York Mellon
New York
$861K +$55.7K +3,250 +8%
AAA
32
Affinity Asset Advisors
New York
$855K +$772K +45,000 New
Wells Fargo
33
Wells Fargo
California
$726K -$199K -11,604 -23%
JP Morgan Chase
34
JP Morgan Chase
New York
$676K +$211K +12,293 +53%
Charles Schwab
35
Charles Schwab
California
$638K +$44.5K +2,597 +8%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$573K -$10.3K -600 -2%
BC
37
Birchview Capital
Vermont
$570K – – –
SFI
38
Susquehanna Fundamental Investments
Pennsylvania
$550K +$497K +28,967 New
Millennium Management
39
Millennium Management
New York
$547K -$583K -33,981 -54%
Two Sigma Investments
40
Two Sigma Investments
New York
$539K +$487K +28,396 New
GCP
41
GSA Capital Partners
United Kingdom
$430K -$48.1K -2,802 -11%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$425K -$1.69M -98,467 -81%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$419K +$28.7K +1,674 +8%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$385K +$348K +20,300 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$361K +$55.5K +3,236 +21%
EP
46
Eversept Partners
New York
$359K -$1.52M -88,375 -82%
AllianceBernstein
47
AllianceBernstein
Tennessee
$357K -$15.4K -900 -5%
Ensign Peak Advisors
48
Ensign Peak Advisors
Utah
$337K +$304K +17,730 New
Barclays
49
Barclays
United Kingdom
$260K -$16.8K -978 -7%
Bank of America
50
Bank of America
North Carolina
$250K -$30.5K -1,778 -12%
1
2
3 4

KALV Hedge Fund Activity: Q4 2020 in Review

82 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2020, worth a combined $303M — up 49% from $203M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new KALV positions and 4 closed out — a net gain of 19 holders — while 22 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $3.41M. The largest seller was Ikarian Capital, cutting an estimated $2.94M.

  • 82 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2020, up from 63 in Q3 2020.
  • Funds reported $303M of KalVista Pharmaceuticals stock for Q4 2020, up 49% quarter-over-quarter.
  • 23 funds opened new KalVista Pharmaceuticals positions in Q4 2020 and 4 closed out, a net change of +19 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2020 was BlackRock, an estimated $3.41M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2020 was Ikarian Capital, an estimated $2.94M sold.

Based on aggregated 13F filings for Q4 2020.